Brief: Lakeshore Biopharma Granted Phase Iii Clinical Trial Approval To Explore Simplified Regimens For Ysja Rabies Vaccine
25/10/2024 14:38
Oct 25 (Reuters) - LakeShore Biopharma Co Ltd H6Z0.F :
* LAKESHORE BIOPHARMA GRANTED PHASE III CLINICAL TRIAL
APPROVAL TO
EXPLORE SIMPLIFIED REGIMENS FOR YSJA RABIES VACCINE
Source text for Eikon: ID:nPn6qNkNma
Further company coverage: H6Z0.F
((Reuters.Briefs@thomsonreuters.com))
Recent news on LakeShore Biopharma Co
See all newsBrief: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
Brief: LakeShore Biopharma Appoints Advisors to Special Committee Reviewing Takeover Bid
Brief: Lakeshore Biopharma Announces Receipt Of A Preliminary Non-Binding Proposal To Acquire The Company
Brief: Lakeshore Biopharma Expects 2026 Revenue To Be Between RMB550 Million And RMB650 Million
Brief: Lakeshore Biopharma Announces Us$15 Million Private Placement Financing